Bicara Therapeutics (BCAX) Leases (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Leases data on file, last reported at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 158.7% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 million (up 158.7% YoY), and the FY2025 full-year result was $1.7 million, up 146.52% from the prior year.
• Leases for Q1 2026 stood at $1.4 million, down from $1.7 million in the prior quarter.
• Across five years, Leases topped out at $2.2 million in Q2 2025 and bottomed at $414000.0 in Q3 2024.
• The 4-year median for Leases is $1.1 million (2024), against an average of $1.2 million.
• The widest annual swing landed in 2024, when Leases climbed 12.56%; it then surged 375.6% in 2025.
• A 4-year view of Leases shows it stood at $613000.0 in 2023, then climbed by 12.56% to $690000.0 in 2024, then soared by 146.52% to $1.7 million in 2025, then slipped by 16.05% to $1.4 million in 2026.
• The last three Leases figures came in at $1.4 million (Q1 2026), $1.7 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.

Peer Comparison